Aortech International PLC
23 August 2002
AorTech International plc
Proposed BD Acquisition
AorTech International plc ('AorTech' or 'Company'), the Scottish-based developer
and manufacturer of cardiovascular devices, announces that it will not be
proceeding with the proposed acquisition of the Critical Care business of BD
(Becton Dickinson and Company).
The Company announced at the time of its Preliminary Results in June that, due
to certain technical issues which arose during the due diligence process,
AorTech would not proceed with the transaction until those issues had been fully
resolved. Upon further review of those issues, the Directors' have concluded
that it would not be in the best interests of AorTech to proceed with the
acquisition.
Eddie McDaid, Chairman of AorTech stated:
'Due to circumstances outside our control, we are unable to conclude the
transaction. It has become apparent that the technical issues, which arose
during the latter part of our due diligence, could not be resolved to our
satisfaction. As a result, it would not be in the interests of AorTech to
proceed.
'We are continuing with the sub-contract manufacture of our TruCCOMS catheters
at BD's plant in Singapore in accordance with our existing agreement.'
Bill Strachan, CEO of AorTech commented:
'I am optimistic that AorTech's range of innovative technologies provides a
strong platform on which to build. We have recently concluded the next phase of
our rationalisation and reorganisation programme and I am pleased that one of
the positive impacts of this review will be a significant reduction in the
Company's cash burn. The management of the Company will continue to focus on
our current technology base, particularly TruCCOMS, Elast-Eon, and the
tri-leaflet heart valve which we believe can create increased value for the
Company.'
23rd August 2002
ENQUIRIES:
AorTech International plc Tel: 01698 746 699
Eddie McDaid, Chairman
Bill Strachan, CEO
Bell Lawrie White & Co Tel: 0141 221 7733
Clive Thomson / Elizabeth Kennedy
College Hill Tel: 020 7457 2020
Michael Padley / Clare Warren
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.